Research Question: Can we improve the management of patients with melanoma using precision medicine aided by artificial intelligence? Background: At present, the management of patients with melanoma is guided by a staging system (AJCC) using limited clinical and pathological information of the tumor. With this system, stratification of risk and clinical management (follow-up, diagnostic tests, treatments) are established. However, relevant prognostic information of the tumor and from the patient is not considered. This fact explains the limited accuracy of the staging system to predict the risk of the patient and to guide clinical management. We propose six linked work packages to build out a precision medicine-oriented method called AID-MM (Artificial Intelligence-Driven Melanoma model) for better guiding clinical management of patients with melanoma. Methods: 1. Identify clinical, environmental, socio-economic, behavioral, phenotypical, biochemical, pharmacological, genetic and medical imaging data which correlate with the patient’s risk to relapse, metastasize or die on a collaborative database which contains information from 23 different hospitals in Catalonia (“Xarxa de Centres de Melanoma”) with more than 600000 entries from at approximately 14000 melanoma patients, 2. Create a survival prediction multimodal Deep Learning algorithm to aggregate the information from a patient into a set of scores to predict disease-free survival and melanoma survival associated risks, and validation of AIM-MM output on European melanoma patients from data registries from two International Societies of cancer (EORTC and EADO), 3. Use the model’s outputs to create a new statistically coherent stratification for patients with melanoma and predict the patient’s outcome under different treatment options, 5. Upload the AID-MM to an online platform for physicians around the world to predict the risk of metastasis, relapse, and death of their patients. Anticipated impact: The “Artificial Intelligence-Driven Melanoma Model” (“AID-MM”) will improve melanoma patients’ care by the implementation of precision medicine.
Fundació La Marato de TV3
Ajuts a projectes de recerca en l'àmbit de salut MARATÓ DE TV3